Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for 4D Molecular Therapeutics, Inc. (FDMT : NSDQ)

• Company Description    4D Molecular Therapeutics Inc. is a clinical-stage gene therapy company which develops product candidates using its targeted and evolved adeno-associated viruses vectors. It offers a portfolio of gene therapy product candidates focusing on the ophthalmology, cardiology and pulmonology therapeutic areas. 4D Molecular Therapeutics Inc. is based in Emeryville, California. Number of Employees: 227

• Price / Volume Information    Yesterday's Closing Price: $10.50 Daily Weekly Monthly 20 Day Moving Average: 993,519 shares Shares Outstanding: 46.70 (millions) Market Capitalization: $490.38 (millions) Beta: 2.96 52 Week High: $12.34 52 Week Low: $2.24 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 17.98% 14.89% 12 Week 44.63% 38.63% Year To Date 88.51% 64.78%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 5858 HORTON STREET #455 - EMERYVILLE,CA 94608 USA ph: 510-505-2680 fax: - investor.relations@4dmt.com http://www.4dmoleculartherapeutics.com

• General Corporate Information    Officers David Kirn - Chief Executive Officer and Director John F. Milligan - Executive Chairman Uneek Mehra - Chief Financial and Business Officer Jacob Chacko - Director Susannah Gray - Director Peer Information 4D Molecular Therapeutics, Inc. (GSAC) 4D Molecular Therapeutics, Inc. (CASI) 4D Molecular Therapeutics, Inc. (ALCD.) 4D Molecular Therapeutics, Inc. (OMNN) 4D Molecular Therapeutics, Inc. (CGPI.) 4D Molecular Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 35104E100 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/12/25 Share - Related Items Shares Outstanding: 46.70 Most Recent Split Date: (:1) Beta: 2.96 Market Capitalization: $490.38 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.72 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.16 Price/Cash Flow: - Price / Sales: 14,859.73 EPS Growth vs. Year Ago Period: -55.56% vs. Previous Quarter: -13.95% Sales Growth vs. Year Ago Period: 200.00% vs. Previous Quarter: 7.14% ROE 09/30/25 - - 06/30/25 - -40.15 03/31/25 - -33.26 ROA 09/30/25 - - 06/30/25 - -36.43 03/31/25 - -30.68 Current Ratio 09/30/25 - - 06/30/25 - 8.75 03/31/25 - 12.36 Quick Ratio 09/30/25 - - 06/30/25 - 8.75 03/31/25 - 12.36 Operating Margin 09/30/25 - - 06/30/25 - -594,375.81 03/31/25 - -767,126.06 Net Margin 09/30/25 - - 06/30/25 - -594,375.81 03/31/25 - -767,126.06 Pre-Tax Margin 09/30/25 - - 06/30/25 - -594,375.75 03/31/25 - -767,126.00 Book Value 09/30/25 - - 06/30/25 - 9.09 03/31/25 - 10.14 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - - 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©